Stephan Wurzer

Jan 9, 2025 | mckinsey.com | Ahsan Saeed |Gaurav Agrawal |Guang Yang |Stephan Wurzer

Leading companies are revamping research and early development to curb lengthy drug development timelines and rising costs. The journey to bring new medicines to market remains long and costly, despite recent technological and process improvements in biopharma R&D. It takes about a decade, on average, from candidate nomination to launch, and study and application costs for investigational new drugs (INDs) have soared in recent years by 20–30 percent.